Biotech: Page 97
-
Lundbeck to cut more than 100 jobs as it remodels R&D
The roughly 130 to 160 positions are in R&D and R&D-related functions, a company spokesperson confirmed, and the majority of them are in Lundbeck's Denmark offices.
By Jacob Bell • June 9, 2020 -
Alnylam details data for kidney disease drug under FDA review
Treatment with lumasiran significantly lowered levels of a key chemical correlated with kidney failure, paving the way for what would be Alnylam's third drug approval.
By Jonathan Gardner • June 8, 2020 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty / Edited by BioPharma Dive
Sarepta, with new data, plans final push for limb-girdle gene therapy
New results show a higher dose of Sarepta's gene therapy outperformed a lower one, a finding its CEO believes should build confidence in several of its other experimental treatments.
By Ben Fidler • June 8, 2020 -
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
The China-based cell therapy developer, whose myeloma therapy is a rival to one from Bristol Myers and Bluebird, outraised this year's previous top initial biotech stock offering.
By Ben Fidler • June 5, 2020 -
Amid a pandemic, Atlas becomes latest venture firm to raise cash for drug startups
Atlas Venture started its 12th fund in March. By early June it had received more than $1 billion in demand, mostly from returning limited partners.
By Jacob Bell • June 5, 2020 -
Jacob Bell/BioPharma Dive
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA
The deal follows similar pacts involving Merck, Biogen, Roche and others, reflecting growing interest by pharmaceutical companies in the emerging field.
By Ben Fidler • June 4, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49535193876/in/album-72157713108522106/.
COVID-19 studies of malaria, blood pressure pills come under scrutiny
The Lancet and The New England Journal of Medicine issued "statements of concern" regarding two high-profile trials they published, citing gaps in a database used by the authors.
By Jonathan Gardner • Updated June 4, 2020 -
Biotech IPOs near last year's pace, despite COVID-19 pandemic
A successful IPO from Pliant Therapeutics is the first of five potential offerings by biotechs this week, suggesting activity is picking up following earlier coronavirus-related disruption.
By Ben Fidler • June 3, 2020 -
Courtesy of Regeneron Pharmaceuticals
Regeneron expands Intellia gene editing deal as its post-Sanofi future emerges
Regeneron and Intellia will grow their alliance and work on hemophilia, an already competitive space that includes several experimental gene therapies.
By Jonathan Gardner • June 1, 2020 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
Details lacking, but new remdesivir data point to a benefit for 'moderate' COVID-19 patients
The results suggest that Gilead's drug may help a broader swath of patients with coronavirus disease, though the magnitude of benefit is unclear.
By Jacob Bell • June 1, 2020 -
Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
Tauvid, which identifies the size and spread of tau protein clusters in the brain, could help Alzheimer's researchers as they shift away from a long-dominant focus on amyloid beta.
By Jacob Bell • May 29, 2020 -
With new Allogene data, same promise, questions surround 'off the shelf' CAR-T
Updated results from Allogene at ASCO's virtual meeting are encouraging, but still don't show whether its allogeneic approach can match autologous CAR-T.
By Ben Fidler • May 29, 2020 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158853/.
Novartis teams with Mass. Eye & Ear to join coronavirus vaccine chase
The Swiss pharma has become the latest large drugmaker to enter the worldwide race to develop a vaccine for COVID-19, tapping a project developed by gene therapy experts at the Massachusetts Eye and Ear Hospital.
By Jonathan Gardner • May 28, 2020 -
Permission granted by Gilead Sciences
U.K. grants early access to Gilead's remdesivir for COVID-19 patients
Supplies of the antiviral drug are tight, however, with many of the doses donated by Gilead reserved for use in the U.S.
By Kristin Jensen • May 27, 2020 -
Permission granted by Gilead Sciences
Gilead puts $375M into Arcus in latest push to broaden cancer business
The alliance, inked two months after a $5 billion buyout of cancer biotech Forty Seven, extends Gilead's effort to establish itself as a major player in oncology.
By Ben Fidler • May 27, 2020 -
Yujin Kim/BioPharma Dive
Deep DiveVenture capital found its footing in biotech. Then came the virus.
There's been no better time for venture firms to invest in drug startups than the past few years. But when a virus upended the world, it raised new questions about what types of investors and investments would succeed moving forward.
By Jacob Bell • May 26, 2020 -
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Intercept shares fall as FDA again delays closely watched NASH drug
The FDA has asked for more data on obeticholic acid, which could be the first-ever marketed medicine for non-alcoholic steatohepatitis. The latest delay means the drug likely won’t be approved by the agency's June 26 deadline.
By Jonathan Gardner • May 22, 2020 -
Sunovion crowds a new group of Parkinson's drugs, with uncertain sales prospects
Kynmobi has become the fourth drug the FDA has approved since late 2018 for the "off" episodes Parkinson's disease patients experience. The coronavirus pandemic may complicate an already challenging launch.
By Ben Fidler • May 22, 2020 -
AstraZeneca, Merck race past Clovis as PARPs break into prostate cancer
The approvals of Lynparza and Rubraca within days of one another mark the arrival of PARP inhibitors as treatments for prostate cancer — a role that could grow in the coming years.
By Ben Fidler • May 20, 2020 -
More questions than answers as Moderna's coronavirus vaccine speeds ahead
Preliminary results from a Phase 1 study were enough to add $5 billion to Moderna's market capitalization. But they don't answer key questions about the vaccine's safety and effectiveness.
By Jonathan Gardner • May 19, 2020 -
Biotech companies raise cash as coronavirus updates lift stocks
Eight publicly traded drugmakers, including Moderna, announced plans Monday to raise nearly $3 billion via offerings of new stock and debt.
By Ned Pagliarulo • May 19, 2020 -
Moderna delivers first human data for a coronavirus vaccine
The first volunteers who received low or medium doses of Moderna's vaccine produced what look to be meaningful immune responses, but it's unclear whether that will lead to disease prevention.
By Ben Fidler • May 18, 2020 -
Safety questions linger as Pfizer preps Duchenne gene therapy for final test
New data presented at the American Society of Gene & Cell Therapy's yearly meeting show promise, but also side effects that haven't been seen with a rival treatment from Sarepta.
By Ben Fidler • May 15, 2020 -
Alex Wong via Getty Images
Ousted BARDA director: Hydroxychloroquine push distracted government scientists
Safety concerns led to a clash over how widely to distribute the malaria pill for use against COVID-19, Rick Bright testified to Congress Thursday.
By Jonathan Gardner • May 14, 2020 -
Cancer biotech stocks shift on glimpse of ASCO data
Data from Allogene was well received by investors, but several other biotechs saw their market value erode following release of ASCO study abstracts.
By Ned Pagliarulo • May 14, 2020
Previous
